Paragon 28 Gestion

Gestion contrôle des critères 3/4

Le PDG Paragon 28 est Albert DaCosta, nommé en Jan2012, a un mandat de 12.83 ans. La rémunération annuelle totale est $ 3.23M, composée du salaire de 21.7% et des bonus 78.3%, y compris les actions et options de la société. détient directement 13.2% des actions de la société, d'une valeur de € 105.75M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3 ans et 3.4 ans.

Informations clés

Albert DaCosta

Directeur général

US$3.2m

Rémunération totale

Pourcentage du salaire du PDG	21.7%
Durée du mandat du directeur général	12.8yrs
Propriété du PDG	13.2%
Durée moyenne d'occupation des postes de direction	3yrs
Durée moyenne du mandat des membres du conseil d'administration	3.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Albert DaCosta a-t-elle évolué par rapport aux bénéfices de Paragon 28?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$56m
Jun 30 2024	n/a	n/a	-US$55m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$3m	US$701k	-US$48m
Sep 30 2023	n/a	n/a	-US$74m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$5m	US$650k	-US$67m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$5m	US$615k	-US$14m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	n/a	n/a	US$4m
Dec 31 2020	US$933k	US$588k	US$3m

Rémunération vs marché: La rémunération totale de Albert ($USD 3.23M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.46M ).

Rémunération et revenus: La rémunération de Albert a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Albert DaCosta (51 yo)

12.8yrs

Titularisation

US$3,232,421

Compensation

Mr. Albert DaCosta is Co-Founder of Paragon 28, Inc. and serves as Chief Executive Officer, President and Director since 2012. Mr. DaCosta is a veteran in the foot and ankle industry with over 18 years of...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Albert DaCosta	Co-Founder	12.8yrs	US$3.23m	13.2% € 106.6m
Robert McCormack	General Counsel & Secretary	1.3yrs	US$1.40m	0.0092% € 74.5k
Matthew Jarboe	Executive VP of Sales & Chief Commercial Officer	6.8yrs	US$1.53m	0.27% € 2.2m
Andrew Hill	Executive Vice President of Research & Development	1.1yrs	US$1.31m	0.091% € 737.7k
Chadi Chahine	CFO & Executive VP of Supply Chain Operations	less than a year	pas de données	0.00040% € 3.2k
Matthew Brinckman	Senior Vice President of Strategy & Investor Relations	2.3yrs	pas de données	pas de données
Brendan Shook	Executive VP of Marketing & Medical Education	5.2yrs	pas de données	pas de données
Matthew Millard	Chief Human Resources Officer	1.7yrs	pas de données	pas de données
John Shumaker	Executive Vice President of Sales - U.S.	3.8yrs	pas de données	pas de données
Hans Kestler	Executive Vice President of International	4.3yrs	pas de données	pas de données
Yuliya Aslan	Senior Vice President of IT	3.8yrs	pas de données	pas de données
Sanket Shah	Senior VP	1.1yrs	pas de données	pas de données

3.0yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 7GQ est considérée comme expérimentée (ancienneté moyenne 3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Albert DaCosta	Co-Founder	12.8yrs	US$3.23m	13.2% € 106.6m
B. Johnson	Independent Director	2.9yrs	US$212.50k	0.032% € 257.7k
Stephen Newman Oesterle	Independent Director	3.8yrs	US$210.00k	0.029% € 234.4k
Thomas Schnettler	Lead Independent Director	4.3yrs	US$245.00k	0.027% € 220.6k
Quentin Blackford	Independent Director	2.3yrs	US$220.00k	0.028% € 229.4k
Meghan Scanlon	Independent Director	2.6yrs	US$210.61k	0.024% € 195.3k
Alf Grunwald	Independent Director	7.8yrs	US$210.00k	0.036% € 287.1k
Kristina Wright	Director	2.9yrs	US$220.00k	0.022% € 179.0k

3.4yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 7GQ sont considérés comme expérimentés (ancienneté moyenne 3.4 ans).

Paragon 28 Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Co-Founder recently bought €234k worth of stock

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

High number of new directors

Insider recently sold €1.1m worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023)

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc

Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury

Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2023)

Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024

Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2023)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought €234k worth of stock

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022)

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

New minor risk - Share price stability

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022)

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021)

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold €1.1m worth of stock

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold €355k worth of stock

Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System

Key Executive recently sold €420k worth of stock

Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.021 loss in 1Q 2021)

Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new directors

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries

Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022

Paragon 28, Inc. Announces Executive Changes